Evidence map›Paper›PMID 42534404›Full record

ReviewJAC-antimicrobial resistance2026

The global epidemiology of MRSA.

Giusy Tiseo, Valentina Galfo, Marco Falcone

Abstract readReview
In one paragraph

Review in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Giusy TiseoInfectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0002-3884-4933
Valentina GalfoInfectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy.
Marco FalconeInfectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0003-3813-8796

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MRSA remains a major global health challenge. Although its global prevalence has declined over the last decade, especially in high-income countries, MRSA still has a high burden of invasive infections and mortality. The global epidemiology of MRSA is characterized by significant regional heterogeneity, shaped by infection control policies and healthcare organization. Distinct epidemiological patterns characterize acute-care hospitals, long-term care facilities and community settings, reflecting differences in population vulnerability and healthcare exposure. At the molecular level, MRSA circulation is sustained by the dynamic coexistence of successful clonal lineages and by the evolving distribution of resistance determinants. MRSA acquisition is driven by a combination of patient-related, environmental and healthcare-associated factors, reflecting the complex interaction between host vulnerability and exposure intensity. On this basis, MRSA nasal screening has emerged as both an infection prevention measure and a key antimicrobial stewardship tool across multiple clinical scenarios. In recent years, therapeutic approaches have evolved, and new effective and safe anti-MRSA agents are currently available.

Identifiers

PMID42534404
PMCPMC13420532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.